Probi AB (publ) (PBBIF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Probi AB (publ) (PBBIF) trades at $24.00 with AI Score 45/100 (Grade C). Probi AB (publ) is a Swedish biotechnology company specializing in the research, development, and sale of probiotics. Market cap: $287M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for PBBIF: PBBIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PBBIF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PBBIF: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Probi AB (publ) (PBBIF) Healthcare & Pipeline Overview
Probi AB (publ) is a Swedish probiotics company that researches, develops, and manufactures probiotic products for health, pharmaceutical, and food industries. With a presence in approximately 40 countries, Probi focuses on gastrointestinal, immune, and bone health, offering dietary supplements and functional foods in various formats.
What Is the Investment Thesis for PBBIF?
Probi AB (publ) presents a focused investment opportunity within the probiotics market. The company's research-driven approach and diverse product formats cater to a broad range of health needs, potentially driving revenue growth. A P/E ratio of 235.75 indicates a high valuation, reflecting market expectations for future growth. Probi's collaborations with universities could lead to innovative product development and expansion into new markets. However, investors may want to evaluate the company's relatively low profit margin of 2.7% and the competitive landscape within the probiotics industry. The company's beta of 0.44 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
PBBIF Key Highlights
Market capitalization of $287M, reflecting its position as a smaller player in the broader healthcare market.
- P/E ratio of 235.75, indicating a premium valuation compared to industry peers, potentially reflecting investor expectations of future growth.
- Gross margin of 35.1%, suggesting moderate profitability in its product sales.
- Beta of 0.44, indicating lower volatility compared to the overall market, which may appeal to risk-averse investors.
- Profit margin of 2.7%, demonstrating a need for improved operational efficiency to enhance profitability.
Who Are PBBIF's Competitors?
PBBIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CLVLF Clinuvel Pharmaceuticals Limited | $7.27 | +0.00% | $366M | 56 |
| CMVLF Cellectis S.A. | $3.47 | +12.66% | $252M | 51 |
| CYDY CytoDyn Inc. | $0.21 | +3.26% | $282M | 47 |
| FGHQF Frontage Holdings Corporation | $0.15 | +0.00% | $304M | 42 |
| HNSBF Hansa Biopharma AB (publ) | $3.70 | +0.00% | $369M | 63 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PBBIF's Key Strengths?
Proprietary probiotic strains with proven health benefits.
- Strong research and development capabilities.
- Established relationships with key industry players.
- Presence in approximately 40 countries worldwide.
What Are PBBIF's Weaknesses?
Relatively low profit margin of 2.7%.
- High P/E ratio suggesting overvaluation.
- Dependence on collaborations for research and development.
- Limited brand recognition compared to larger competitors.
What Could Drive PBBIF Stock Higher?
PBBIF catalyst: Results from the clinical trial collaboration with La Trobe University regarding the effect of Probi Osteo in Australian women could drive investor interest.
- Expansion into new geographic markets, particularly in emerging economies, could lead to increased revenue and profitability.
- Development and commercialization of novel probiotic strains with specific health benefits could create a competitive advantage.
- Strategic partnerships with food and beverage companies to incorporate Probi's probiotic strains into their products could expand market reach.
- Increasing consumer awareness of the benefits of probiotics for gut health and overall well-being could drive demand for Probi's products.
What Are the Key Risks for PBBIF?
Increasing competition from established players in the probiotics market could erode market share and pricing power.
- Evolving regulatory landscape for probiotic products could increase compliance costs and limit product claims.
- Scientific uncertainty regarding the efficacy of certain probiotic strains could negatively impact consumer confidence.
- The company's relatively low profit margin of 2.7% could limit its ability to invest in growth initiatives.
- Dependence on collaborations for research and development could expose the company to risks associated with partner performance.
What Are the Growth Opportunities for PBBIF?
- Expansion into new geographic markets: Probi has the opportunity to expand its presence beyond its current reach of 40 countries. Targeting emerging markets with growing disposable incomes and increasing health awareness could significantly boost revenue. Focus on regions with limited access to probiotic products could provide a first-mover advantage. This expansion could be achieved through strategic partnerships, distribution agreements, or direct investment in local operations. Timeline: Ongoing.
- Development of novel probiotic strains: Investing in research and development to discover and patent new probiotic strains with specific health benefits can create a competitive advantage. Focusing on areas such as personalized nutrition and targeted therapies could lead to high-value products. Collaborations with research institutions and universities can accelerate the discovery process. Successful development and commercialization of novel strains can drive revenue growth and enhance Probi's reputation as an innovator. Timeline: Ongoing.
- Strategic partnerships with food and beverage companies: Collaborating with major food and beverage companies to incorporate Probi's probiotic strains into their products can provide access to a wider consumer base. Developing customized probiotic solutions for specific food and beverage applications can create value for both Probi and its partners. These partnerships can lead to increased sales volume and brand recognition. Timeline: Ongoing.
- Focus on women's health: Probi can capitalize on the growing demand for women's health products by developing probiotic solutions specifically tailored to address women's health needs, such as vaginal health, prenatal care, and menopausal symptoms. This targeted approach can attract a loyal customer base and differentiate Probi from competitors. Clinical trials demonstrating the efficacy of these products can further enhance their appeal. Timeline: Ongoing.
- Expansion into the pet health market: The pet health market is experiencing significant growth, driven by increasing pet ownership and a growing awareness of the benefits of probiotics for pets. Probi can leverage its expertise in probiotics to develop and market probiotic supplements for dogs, cats, and other pets. This expansion can diversify Probi's revenue streams and tap into a new and growing market. Timeline: Ongoing.
What Are PBBIF's Competitive Advantages?
- Proprietary probiotic strains: Probi's patented probiotic strains provide a competitive advantage and differentiation in the market.
- Research and development capabilities: The company's focus on research and development allows it to innovate and develop new probiotic solutions.
- Established relationships with health, pharmaceutical, and food companies: Probi's existing relationships provide access to established distribution channels and customer networks.
- Scientific expertise: Probi's team of scientists and researchers provides a deep understanding of probiotics and their health benefits.
What Does PBBIF Do?
Probi AB (publ), founded in 1991 and headquartered in Lund, Sweden, is a biotechnology company focused on probiotics. It researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. The company's research primarily targets gastrointestinal health, digestive health, immune health, bone health, and iron absorption, as well as solutions for children's, women's, and senior health. Probi offers its products in various forms, including capsules, tablets, chewable tablets, powders, fruit drinks, shots, carbonated beverages, and recovery drinks. Probi has expanded its reach to approximately 40 countries worldwide. The company actively engages in collaborations, such as its research partnership with Örebro University for needle-free vaccines and its clinical trial collaboration with La Trobe University to study the effects of Probi Osteo on women's bone health. Probi AB (publ) operates as a subsidiary of Symrise AG, a global supplier of fragrances, flavorings, cosmetic active ingredients and raw materials, as well as functional ingredients.
What Products and Services Does PBBIF Offer?
- Researches and develops probiotic strains for various health applications.
- Manufactures probiotic products in different formats, including capsules, tablets, and powders.
- Markets and sells probiotic products to health, pharmaceutical, and food companies.
- Focuses on probiotic solutions for gastrointestinal, digestive, immune, and bone health.
- Collaborates with universities and research institutions to explore new probiotic applications.
- Provides probiotic ingredients for dietary supplements, food, and beverage products.
How Does PBBIF Make Money?
- Develops and patents proprietary probiotic strains.
- Manufactures probiotic products and ingredients.
- Sells probiotic products and ingredients to health, pharmaceutical, and food companies.
- Generates revenue through product sales and licensing agreements.
What Industry Does PBBIF Operate In?
Probi AB (publ) operates within the growing probiotics market, driven by increasing consumer awareness of gut health and its impact on overall well-being. The industry is characterized by a mix of large pharmaceutical companies, specialized biotech firms, and food and beverage companies incorporating probiotics into their products. Competitors include companies like CLVLF, CMVLF, CYDY, FGHQF, and HNSBF. The market is subject to evolving regulatory landscapes and increasing scientific scrutiny regarding the efficacy of probiotic strains. The global probiotics market is expected to continue to grow, fueled by demand for preventative healthcare solutions.
Who Are PBBIF's Key Customers?
- Health companies that incorporate probiotics into their supplement formulations.
- Pharmaceutical companies that develop probiotic-based therapies.
- Food and beverage companies that add probiotics to their products.
- Consumers who purchase probiotic-containing products through various channels.
Key Financial Metrics
Return on equity for Probi AB (publ) stands at 1.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.1%, showing how much profit it generates from its asset base. PBBIF trades at a trailing price-to-earnings ratio of 235.75, above the Healthcare sector average of ~23x. Its free cash flow yield is 0.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.94 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.4%, the inverse of the P/E and a quick read on earnings relative to price.
Probi AB (publ) (PBBIF) Valuation Context
Valued at $287M, PBBIF is classified as a micro-cap stock. Relative to its peer group, PBBIF's quantitative score of 45/100 is roughly in line with the peer average of 52/100.
Company Profile
Probi AB (publ) operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Lund, SE. The company is led by CEO Anita Johansen. PBBIF has traded publicly since 2016.
Financial Health
Probi AB (publ)'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.82 places it in the grey zone, a middle ground that warrants monitoring.
Forward Outlook
Wall Street analysts project Probi AB (publ) revenue of about $65.3M for fiscal 2026, with EPS near $0.37.
PBBIF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Probi AB has seen increased insider buying, suggesting confidence from leadership in the company's direction.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative product pipeline.
- Recent partnerships in the health sector have bolstered Probi's reputation, enhancing its market perception.
- The growing interest in probiotics and gut health aligns well with Probi's offerings, attracting consumer attention.
Bear Case
- Some analysts express concerns over the competitive landscape in the probiotics market, which could impact growth.
- Recent social media sentiment has shown skepticism regarding Probi's ability to scale effectively in a crowded market.
- There are ongoing challenges related to regulatory approvals that could delay product launches.
- Market perception is mixed, with some investors worried about the sustainability of current growth trends.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PBBIF Latest News
No recent news available for PBBIF.
PBBIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PBBIF.
Price Targets
Wall Street price target analysis for PBBIF.
PBBIF MoonshotScore
What does this score mean?
The MoonshotScore rates PBBIF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Anita Johansen
CEO
Anita Johansen is the CEO of Probi AB (publ). Information regarding her detailed career history, education, and previous roles is not available in the provided data. As CEO, she is responsible for leading the company's strategic direction, overseeing operations, and driving growth in the probiotics market. She manages a workforce of 157 employees.
Track Record: Specific achievements, strategic decisions, and company milestones under Anita Johansen's leadership are not available in the provided data. Her role involves guiding Probi AB (publ) in its research, development, manufacturing, and marketing of probiotic products.
PBBIF OTC Market Information
The OTC Other tier, where PBBIF trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. These companies may not meet the minimum listing requirements of higher-tier OTC markets or major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries significantly higher risks due to the lack of transparency and regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure: The lack of comprehensive financial information makes it difficult to assess the company's financial health and performance.
- Low liquidity: Limited trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Price volatility: OTC stocks are often subject to greater price swings due to lower trading volume and speculative trading.
- Potential for fraud or manipulation: The OTC market is less regulated than major exchanges, increasing the risk of fraudulent or manipulative activities.
- Going concern risk: Companies trading on the OTC Other tier may be at risk of financial distress or bankruptcy.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements, even if limited.
- Assess the company's business model and competitive landscape.
- Research the company's management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Monitor the company's news and announcements for any red flags.
- Subsidiary of Symrise AG: Being a subsidiary of Symrise AG, a larger and more established company, could lend some credibility.
- Global presence: Operating in approximately 40 countries suggests a degree of operational scale and market acceptance.
- Research collaborations: Collaborations with universities like Örebro University and La Trobe University suggest a commitment to scientific research and development.
- Focus on probiotics: Specialization in probiotics, a growing area of interest in health and wellness, could indicate a viable business.
What Investors Ask About Probi AB (publ) (PBBIF) — Healthcare
What does the AI Score mean for PBBIF?
PBBIF holds an AI Score of 45/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Probi AB (publ) is a Swedish biotechnology company specializing in the research, development, and sale of probiotics. Their products are marketed globally to health, pharmaceutical, and food …
What does Probi AB (publ) do?
Probi AB (publ) is a Swedish biotechnology company specializing in the research, development, manufacture, marketing, and sale of probiotics. They develop probiotic strains and incorporate them into various product formats, including capsules, tablets, powders, and beverages. These products are sold to health, pharmaceutical, and food companies for use in dietary supplements, functional foods, and pharmaceutical applications.
What are the main risks for PBBIF?
Investing in PBBIF carries several risks, including increasing competition in the probiotics market, evolving regulatory requirements for probiotic products, and scientific uncertainty regarding the efficacy of certain probiotic strains. The company's relatively low profit margin of 2.7% and dependence on collaborations for research and development also pose risks.
What are the key factors to evaluate for PBBIF?
Probi AB (publ) (PBBIF) holds an AI score of 45/100 (low). Probi AB (publ) presents a focused investment opportunity within the probiotics market. Not financial advice.
How frequently does PBBIF data refresh on this page?
PBBIF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PBBIF's recent stock price performance?
Probi AB (publ) (PBBIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary probiotic strains with proven health benefits. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PBBIF overvalued or undervalued right now?
Probi AB (publ) (PBBIF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PBBIF before investing?
Before investing in Probi AB (publ) (PBBIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding PBBIF to a portfolio?
Key strength of Probi AB (publ) (PBBIF): Proprietary probiotic strains with proven health benefits. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO's background and track record.
- OTC market data may be less reliable than major exchange data.
- Analyst consensus data is not available.